New hope for brittle bones? first human test of osteoporosis drug begins
NCT ID NCT07178327
Summary
This is the first-ever study in people for a new drug called LYN101. The main goal is to check its safety and how the body processes it. It will first be given as a single dose to healthy volunteers, and then as multiple doses to a small group of postmenopausal women with low bone mass to see how it affects bone health markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Sixth People's Hospital
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233060, China
Conditions
Explore the condition pages connected to this study.